Free Trial

Corvus Pharmaceuticals (CRVS) Stock Price, News & Analysis

-0.04 (-1.83%)
(As of 05/22/2024 ET)
Today's Range
50-Day Range
52-Week Range
132,119 shs
Average Volume
346,730 shs
Market Capitalization
$133.86 million
P/E Ratio
Dividend Yield
Price Target

Corvus Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
221.3% Upside
$6.88 Price Target
Short Interest
3.69% of Float Sold Short
Dividend Strength
News Sentiment
Insider Trading
Acquiring Shares
$1.03 M Bought Last Quarter
Proj. Earnings Growth
From ($0.49) to ($0.58) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.71 out of 5 stars

Medical Sector

419th out of 920 stocks

Pharmaceutical Preparations Industry

182nd out of 424 stocks

CRVS stock logo

About Corvus Pharmaceuticals Stock (NASDAQ:CRVS)

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

CRVS Stock Price History

CRVS Stock News Headlines

13 Penny Stocks with Insider Buying in 2024
Q1 2024 Corvus Pharmaceuticals Inc Earnings Call
Corvus Pharmaceuticals, Inc. (CRVS)
Q4 2023 Corvus Pharmaceuticals Inc Earnings Call
CRVS Apr 2024 4.000 put
CRVS Mar 2024 3.000 put
Corvus Edges up on Disclosing Data
See More Headlines
Receive CRVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corvus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
3 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$0.53 per share


Free Float
Market Cap
$133.86 million
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Dr. Richard A. Miller M.D. (Age 73)
    Co-Founder, President, CEO & Chairman of the Board
    Comp: $306k
  • Dr. Peter A. Thompson FACP (Age 64)
    M.D., Co-Founder & Independent Director
    Comp: $47k
  • Mr. Leiv Lea (Age 70)
    Chief Financial Officer
    Comp: $388.73k
  • Dr. William Benton Jones Ph.D. (Age 58)
    Senior Vice President of Pharmaceutical Development
    Comp: $346.42k
  • Dr. James T. Rosenbaum M.D.
    Senior Vice President of Research
  • Mr. Jeffrey S. Arcara
    Chief Business Officer

CRVS Stock Analysis - Frequently Asked Questions

Should I buy or sell Corvus Pharmaceuticals stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Corvus Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CRVS shares.
View CRVS analyst ratings
or view top-rated stocks.

What is Corvus Pharmaceuticals' stock price target for 2024?

3 equities research analysts have issued 1-year price objectives for Corvus Pharmaceuticals' shares. Their CRVS share price targets range from $3.50 to $12.00. On average, they predict the company's stock price to reach $6.88 in the next twelve months. This suggests a possible upside of 221.3% from the stock's current price.
View analysts price targets for CRVS
or view top-rated stocks among Wall Street analysts.

How have CRVS shares performed in 2024?

Corvus Pharmaceuticals' stock was trading at $1.76 at the beginning of the year. Since then, CRVS shares have increased by 21.6% and is now trading at $2.14.
View the best growth stocks for 2024 here

When is Corvus Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024.
View our CRVS earnings forecast

How were Corvus Pharmaceuticals' earnings last quarter?

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) announced its earnings results on Tuesday, March, 19th. The company reported ($0.14) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.14).

What is Richard A. Miller, MD's approval rating as Corvus Pharmaceuticals' CEO?

4 employees have rated Corvus Pharmaceuticals Chief Executive Officer Richard A. Miller, MD on Richard A. Miller, MD has an approval rating of 100% among the company's employees. This puts Richard A. Miller, MD in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 73.0% of employees surveyed would recommend working at Corvus Pharmaceuticals to a friend.

What other stocks do shareholders of Corvus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corvus Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Dynavax Technologies (DVAX), Vaxart (VXRT), Zosano Pharma (ZSAN), SCYNEXIS (SCYX), Miragen Therapeutics (MGEN), Aldeyra Therapeutics (ALDX) and Bionano Genomics (BNGO).

When did Corvus Pharmaceuticals IPO?

Corvus Pharmaceuticals (CRVS) raised $75 million in an IPO on Wednesday, March 23rd 2016. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Credit Suisse and Cowen and Company acted as the underwriters for the IPO and Guggenheim Securities, Cantor Fitzgerald and BTIG were co-managers.

Who are Corvus Pharmaceuticals' major shareholders?

Corvus Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.05%), Towerview LLC (0.78%), BVF Inc. IL (0.74%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Ecor1 Capital, Llc, Leiv Lea, Linda Grais, Orbimed Advisors Llc, Richard A Md Miller and William Benton Jones.
View institutional ownership trends

How do I buy shares of Corvus Pharmaceuticals?

Shares of CRVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CRVS) was last updated on 5/23/2024 by Staff

From Our Partners